Pregnancy Of Unknown Location (PUL)

What providers need to know about managing medication abortion in very early pregnancy

Partner treatment for BV, pain and bleeding experiences during first-trimester abortion, interest in Rh testing and treatment for telehealth medication abortion.

Intrauterine mepivacaine for IUD placement, the impact of abortion restrictions on medical training, pregnancy of unknown location and very early medication abortion, and navigating abortion misinformation

Ongoing support for forgoing Rh testing in early pregnancy, medication abortion before six weeks, provider bias on contraceptive counseling adolescents, and local anesthesia before procedural abortion.

Continued support for misoprostol-only regimens for medication abortion and self-managed abortion between nine and 16 weeks gestation, the use of home pregnancy tests for follow-up care after a telehealth medication abortion, where adolescents and young adults go online to get abortion information, and disparities in recommended retesting for women with trichomonas vaginalis infections.

Initial reports from the ongoing narrative collection Care Post Roe documenting poor-quality care, patient perspectives on telehealth medication abortion, adolescent preferences and experiences with pregnancy options counseling, and more.

A systemic review of “no-test” medication abortion, using an allis clamp during IUD placement, a trial of gabapentin for pain management during second-trimester abortions, and at-home urine pregnancy testing for follow-up of immediate management of an undesired pregnancy of unknown location.

Improved patient satisfaction with the implementation of One Key Question in primary care and OB/GYN care settings, increasing access to STI screening for adolescents and young adults, the need to improve contraceptive care for patients with a history of intimate partner violence, and more.